Open Orphan article published in Drug Discovery Today

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced an article submission has been published in Drug Discovery Today, a print and online trade magazine with an emphasis on the science which underpins drug discovery and development. The published editorial is titled “Modelling the World – can deliberately infecting healthy volunteers really tell us much about what happens outside the clinic during an epidemic or pandemic?”

The article was written by Adrian Wildfire, Director of Scientific and Business Strategy at hVIVO, part of Open Orphan plc. Adrian is a specialist in the fields of virology, medical microbiology and parasitology.

The article explores what can be learned from using the method of human challenge trials to support vaccine development, and focuses on the role hVIVO plays in this, in particular in relation to COVID-19. hVIVO has a long history of successfully delivering human challenge studies at their state-of-the-art quarantine facility in East London.

To view the article, please follow the link: https://bit.ly/3nLct9Q

Interested in becoming a volunteer?

hVIVO recruits many of its volunteers for its challenge study clinical trials through its dedicated volunteer recruitment website, www.flucamp.com. hVIVO welcomes volunteers under expertly supervised conditions, to further medical research, and help us to take the understanding of respiratory illnesses to a new level. Volunteers are central to the work that we do; our studies focus on testing new treatments on real people, in a safe, controlled, clinical environment.

Further details on all aspects of our volunteer programs including testimonials from previous volunteers can be found at www.flucamp.com.

If you are interested in being contacted and provided with details about future COVID-19 human challenge study research, please leave your contact details at www.UKCovidChallenge.com.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

CMC regulatory team capabilities

For 20+ years, members of the CMC regulatory team supported several (bio)pharmaceutical companies to ensure manufacture of safe, effective, and high-quality drug products for patients globally. The support includes: Independent, trusted advice on your regulatory activities

Open Orphan Plc

How to build up your child’s immune system

Our Top 7 Tips to Boots Your Child’s Immune System Protecting your children from germs, bacteria and illnesses is a common concern for parents. Flu, colds, viruses and infections can cause misery for both you and

Open Orphan Plc

Open Orphan’s hVIVO presenting at the World Vaccine Congress

Open Orphan plc (LON:ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a

Open Orphan Plc

Hay fever season is back with a vengeance

Hay Fever is back! As the most common form of non-infectious rhinitis, hay fever affects 10-30% of adults and up to 40% of children. Hay fever season typically starts in mid-March as trees bloom until May.

Open Orphan Plc

Open Orphan Investor Presentation March 2022 (Video)

Open Orphan plc (LON:ORPH) CEO Yamin ‘Mo’ Khan talks through its March 2022 Investor Presentation. Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and

Open Orphan Plc

Strategies for Non-clinical safety assessment of vaccines

Setting the scene Over the past century, vaccines have made a large impact on public health, as recently demonstrated by the treatment of the worldwide Covid-pandemic. Since, in general, vaccines are administered to healthy individuals, including

Open Orphan Plc

Open Orphan’s hVIVO signs €6m contract for respiratory study

Dublin-listed clinical trials group Open Orphan has announced that its subsidiary Hvivo has signed a £5 million (€6m) human challenge study contract with a European biotechnology company. The study will test the company’s intravenous antiviral candidate for respiratory syncytial virus,

Open Orphan Plc

Open Orphan opens two new testing facilities

Specialist pharmaceutical services clinical research company Open Orphan is opening a new primary FluCamp volunteer recruitment screening facility in London and a secondary FluCamp recruitment facility in Manchester. Open Orphan tests vaccines and antivirals using human

Open Orphan Plc

FluCamps’ UK Covid Challenge summary

FluCamps’ parent company hVIVO recently published results for the world’s first COVID-19 human challenge trial, World’s first COVID-19 Characterisation Study (investis.com), which ran in Spring of 2021. FluCamp recruited 36 volunteers for this trial under the title

Open Orphan Plc

Clinical PK and PD Service at Venn Breda

For more than 20 years, the clinical pharmacokinetic (PK: understanding the kinetics of a drug in terms of absorption, distribution, metabolism and elimination [ADME]) and pharmacodynamic (PD: the biochemical and physiological effects of a drug) team

Open Orphan Plc

Open Orphan names Khan as new CEO

Specialist pharmaceutical services clinical research company Open Orphan has appointed Yamin ‘Mo’ Khan as its chief executive with immediate effect. Mr Khan joined the company’s board as a non-executive director in October 2021 and has worked